Close Menu

NEW YORK (360Dx) – Cell-based diagnostics firm Celcuity reported after the close of the market on Thursday that its fourth quarter net losses widened year over year.

For the three months ended Dec. 31, 2017 Celcuity posted a net loss of $1.7 million, or $.17 per share, compared to a net loss of $902,434, or $.14 per share, in the year-ago period. The firm's adjusted loss per share for Q4 2017 was $.14.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
29
Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.